Search

Your search keyword '"Poon, Michelle Limei"' showing total 4 results
Start Over Author "Poon, Michelle Limei" Search Limiters Peer Reviewed
4 results on '"Poon, Michelle Limei"'

1. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella

Published
2022
Full Text
View/download PDF

2. Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study.

Author

Chang, Esther Wei Yin, Yang, Valerie Shiwen, Ong, Shin Yeu, Kang, Hilda Xueqi, Lim, Boon Yee, de Mel, Sanjay, Ng, Esther Ka Yan, Poon, Michelle Limei, Tan, Ya Hwee, Chiang, Jianbang, Poon, Eileen, Somasundaram, Nagavalli, Farid, Mohamad, Tang, Tiffany, Tao, Miriam, Khoo, Lay Poh, Cheng, Chee Leong, Huang, Dachuan, Ong, Choon Kiat, and Lim, Soon Thye

Subjects
T cells, LYMPHOMAS, T helper cells, LACTATE dehydrogenase, BONE marrow
Abstract

In our Asian multicenter retrospective study, we investigated the clinical prognostic factors affecting the outcomes of AITL patients and identified a novel prognostic index relevant in the Asian context. In our 174-patient cohort, the median PFS and OS was 1.8 years and 5.6 years respectively. Age > 60, bone marrow involvement, total white cell count >12 × 109/L and raised serum lactate dehydrogenase were associated with poorer PFS and OS in multivariate analyses. This allowed for a prognostic index (AITL-PI) differentiating patients into low (0-1 factors, n = 64), moderate (2 factors, n = 59) and high-risk (3-4 factors, n = 49) subgroups with 5-year OS of 84.0%, 44.0% and 28.0% respectively (p < 0.0001). POD24 proved to be strongly prognostic (5-year OS 24% vs 89%, p < 0.0001). Exploratory gene expression studies were performed and disparate immune cell profiles and cell signaling signatures were seen in the low risk group as compared to the intermediate and high risk groups. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Cota Stirner, Mariana, Kilavuz, Nurgul, Chiu, Christopher, Chen, Menghui, Sacchi, Mariana, and Elliott, Brian

Published
2023
Full Text
View/download PDF

4. Disease Risk Index (DRI) and Conditioning Regimen Based Risk Stratification of Outcome Among Adults with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.

Author

Yip, Alexander, Tai, Bee Choo, Linn, Yeh Ching, Tan, Lip Kun, Poon, Michelle Limei, Lim, Ziyi, Tan, Belinda, Lim, Yelly, Soh, Teck-Guan, Del Rosario, Davanaliz R., Hwang, William Y.K., and Koh, Liang Piu

Subjects
*ACUTE myeloid leukemia treatment, *HEMATOPOIETIC stem cell transplantation, *HEALTH outcome assessment, *HEMATOLOGY, *MEDICAL publishing, DISEASES in adults
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results